BioCryst presents evidence on high adherence, persistence rates with ORLADEYO

BioCryst (BCRX) Pharmaceuticals announced new real-world comparative research on the use of oral, once-daily ORLADEYO that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with two other long-term prophylactic therapies for hereditary angioedema. The company also announced new real-world evidence showing statistically significant and sustained HAE attack rate reductions after initiating ORLADEYO in patients with HAE, regardless of their C1-inhibitor deficiency status, and new findings from an HAE patient survey confirming patient preference for an oral LTP therapy. The data are being presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, which is taking place in Boston from October 24-28, 2024. High Adherence and Persistence Rates for ORLADEYO and Other LTP Therapies: Poster #R072 explores adherence and persistence rates among patients with HAE following initiation of ORLADEYO compared with lanadelumab and subcutaneous plasma-derived C1-inhibitor. Adherence And Persistence Among Hereditary Angioedema Patients Treated With Berotralstat, Lanadelumab, And Subcutaneous Plasma-Derived C1-Inhibitor; Eighty-six percent of patients who took ORLADEYO, 91 percent who took lanadelumab and 83 percent who took SC-pdC1-INH filled at least two prescriptions during the 12-month follow-up period. Adherence rates among patients with at least two fills were high at 12 months of follow-up. Seventy-seven percent of patients taking ORLADEYO were adherent compared to 76 percent of patients taking lanadelumab and 80 percent of patients taking SC-pdC1-INH. Persistence rates among patients with at least two fills were high at 12 months of follow-up, with 71 percent of patients taking ORLADEYO persistent compared to 63 percent of patients taking lanadelumab and 63 percent of patients taking SC-pdC1-INH. No statistically significant differences in adherence or persistence were observed between the LTP patient cohorts. Posters #R092 and #R093 evaluate self-reported HAE attacks prior to and following ORLADEYO initiation among patients with and without HAE with C1-inhibitor deficiency. respectively. Sustained Real-World Attack Reductions Following Berotralstat Initiation Among Patients with Hereditary Angioedema with C1-Inhibitor Deficiency; ePoster #R092; Friday, October 25, 3:30-3:45 p.m. ET; Monitor #20, Hall A: Patients had significantly lower attack rates at each follow-up interval, which ranged from 0.62 attacks per month at days 361-450 to 0.79 at days 271-360 versus baseline. Mean monthly attack rate reduction was -1.71 at days 271-360 and -1.96 at days 451-540. Sustained Real-World Attack Reductions Following Berotralstat Initiation Among Patients with Hereditary Angioedema without C1-Inhibitor Deficiency; ePoster #R093; Friday, October 25, 3:45-4:00 p.m. ET; Monitor #20, Hall A: Patients had significantly lower attack rates at each follow-up interval, which ranged from 1.63 attacks per month at days 181-270 to 2.04 at days 1-90 versus baseline. Mean monthly attack rate reduction was -2.91 at days 271-360 and -2.53 at days 451-540. Poster #R081 examines the LTP treatment preferences of patients with HAE, as collected through an online survey. Long-Term Prophylactic Treatment Preferences of Patients With Hereditary Angioedema; ePoster #R081; Friday, October 25, 4:45-5:00 p.m. ET; Monitor #19, Hall A LTP treatment attributes rated most important were effectiveness in attack prevention and effectiveness in reducing attack severity. When presented with the option of an equally effective oral or injectable LTP, 54 percent preferred an oral daily therapy over a biweekly or monthly subcutaneous injection. More than half preferred oral over injectable LTP as infrequently as every three months.